Exacerbation data
Placebo | Salbutamol | Salmeterol | |
---|---|---|---|
Number during each treatment period | |||
Total | 97 | 92 | 35 |
Minor | 69 | 58 | 20 |
Major | 28 | 34 | 15 |
Number of patients without exacerbations during each period (%) | |||
Total | 72.1 | 73.5 | 84.98-151 |
Minor | 76.6 | 76.8 | 89.58-151 |
Major | 88.3 | 89.4 | 91.5 |
Corrected exacerbation rate (number per patient per year) | |||
Total | 1.37 (1.11 to 1.67) | 1.39 (1.12 to 1.71) | 0.518-159 (0.35 to 0.70) |
Minor | 0.97 (0.76 to 1.23) | 0.88 (0.67 to 1.13) | 0.298-159 (0.18 to 0.45) |
Major | 0.40 (0.26 to 0.57) | 0.51 (0.36 to 0.72) | 0.228-152(0.12 to 0.36) |
Mean duration per exacerbation (days) | |||
Total | 4.4 (3.6 to 5.2) | 4.5 (3.8 to 5.2) | 3.6 (2.6 to 4.6) |
Minor | 4.0 (3.4 to 4.7) | 3.7 (3.0 to 4.4) | 2.8 (2.3 to 3.3) |
Major | 5.4 (3.2 to 7.6) | 5.8 (4.5 to 7.1) | 4.7 (2.7 to 6.8) |
Mean time spent in exacerbation per patient (days) | |||
Total | 10.0 (7.2 to 12.8) | 10.3 (6.1 to 14.5) | 5.5 (2.8 to 8.2) |
Minor | 7.7 (5.5 to 9.9) | 6.2 (4.6 to 7.8) | 3.5 (2.2 to 4.6) |
Major | 8.4 (5.2 to 11.6) | 12.38-150 (4.2 to 20.4) | 5.5 (1.8 to 9.3) |